This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Becton Dickinson Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Becton Dickinson has been growing earnings at an average annual rate of 24.7%, while the Medical Equipment industry saw earnings growing at 9.9% annually. Revenues have been growing at an average rate of 4.7% per year. Becton Dickinson's return on equity is 6.4%, and it has net margins of 8.3%.

Información clave

24.7%

Tasa de crecimiento de los beneficios

23.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	8.9%
Tasa de crecimiento de los ingresos	4.7%
Rentabilidad financiera	6.4%
Margen neto	8.3%
Última actualización de beneficios	31 Mar 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Becton Dickinson. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NYSE:BDXB Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 23	18,809	1,556	4,791	1,266
31 Dec 22	18,738	1,486	4,751	1,255
30 Sep 22	18,870	1,545	4,726	1,256
30 Jun 22	18,958	1,413	4,774	1,324
31 Mar 22	18,924	1,430	4,845	1,339
31 Dec 21	18,534	1,079	4,750	1,302
30 Sep 21	19,131	1,514	4,720	1,279
30 Jun 21	19,066	1,486	4,632	1,210
31 Mar 21	18,313	1,379	4,409	1,142
31 Dec 20	18,207	1,507	4,346	1,117
30 Sep 20	16,074	245	4,178	1,039
30 Jun 20	16,917	786	4,216	1,067
31 Mar 20	17,414	923	4,313	1,057
31 Dec 19	17,355	760	4,379	1,044
30 Sep 19	17,290	1,081	4,334	1,032
30 Jun 19	17,108	784	4,345	1,039
31 Mar 19	17,036	926	4,353	1,063
31 Dec 18	17,063	894	4,325	1,071
30 Sep 18	15,983	159	4,029	1,004
30 Jun 18	14,747	621	3,689	947
31 Mar 18	13,503	-99	3,325	857
31 Dec 17	12,251	294	2,991	783
30 Sep 17	12,093	1,030	2,953	770
30 Jun 17	12,158	759	2,947	807
31 Mar 17	12,321	1,314	2,957	827
31 Dec 16	12,419	1,309	2,966	823
30 Sep 16	12,483	976	3,005	828
30 Jun 16	12,312	1,139	2,966	771
31 Mar 16	12,234	810	2,988	743
31 Dec 15	11,217	688	2,767	690
30 Sep 15	10,282	695	2,563	632
30 Jun 15	9,410	815	2,350	570
31 Mar 15	8,448	1,079	2,127	529
31 Dec 14	8,468	1,150	2,141	527
30 Sep 14	8,446	1,185	2,145	524
30 Jun 14	8,345	974	2,117	522
31 Mar 14	8,239	941	2,102	506
31 Dec 13	8,169	930	2,091	502
30 Sep 13	8,054	929	2,059	494
30 Jun 13	7,920	1,114	2,004	490
31 Mar 13	7,848	1,132	1,960	484
31 Dec 12	7,776	1,131	1,934	478
30 Sep 12	7,708	1,110	1,920	472
30 Jun 12	7,729	1,120	1,913	468

Ingresos de calidad: BDXB has high quality earnings.

Margen de beneficios creciente: BDXB's current net profit margins (8.3%) are higher than last year (7.6%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: BDXB has become profitable over the past 5 years, growing earnings by 24.7% per year.

Acelerando crecimiento: BDXB's earnings growth over the past year (8.8%) is below its 5-year average (24.7% per year).

Beneficios vs. Industria: BDXB earnings growth over the past year (8.8%) exceeded the Medical Equipment industry 1.2%.

This company listing is no longer active

Becton Dickinson Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Información clave

Actualizaciones de resultados anteriores recientes

Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023

Becton, Dickinson and Company to Report Q1, 2023 Results on Feb 02, 2023

Becton, Dickinson and Company to Report Fiscal Year 2022 Results on Nov 10, 2022

Becton, Dickinson and Company to Report Q3, 2022 Results on Aug 04, 2022

Becton, Dickinson and Company to Report Q2, 2022 Results on May 05, 2022

Becton, Dickinson and Company to Report Q1, 2021 Results on Feb 04, 2021

Recent updates

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion System

Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023

STERIS Corporation agreed to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million.

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test

Becton, Dickinson and Company Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery

Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023

BD (Becton, Dickinson and Company) Declares Quarterly Dividend, Payable on March 31, 2023

Becton, Dickinson and Company Introduces Fully Automated Robotic Track System for Microbiology Labs

Becton, Dickinson and Company and CerTest Biotec Announce Emergency Use Authorization from U.S. Food and Drug Administration for Molecular Polymerase Chain Reaction Assay for Mpox Virus Detection

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company to Report Q1, 2023 Results on Feb 02, 2023

Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023

Becton, Dickinson and Company Board Increases Quarterly Dividend, Payable on December 30, 2022

Becton, Dickinson and Company to Report Fiscal Year 2022 Results on Nov 10, 2022

Becton, Dickinson and Company Appoints Eric Borin President of Medication Delivery Solutions

BD Launches Cloud Software Solution to Streamline Flow Cytometry Research

BD, Certest Biotec Announce US Commercial Launch of Monkeypox Assay

Becton, Dickinson and Company Launches Next Generation Prefillable Vaccine Syringe Designed for Reliability, Efficiency

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company Raises Revenue Guidance for the Full-Year 2022

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Becton, Dickinson and Company Certest Biotec Announce Commercial Launch of Monkeypox Test

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2022

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Parata Systems, LLC from Frazier Healthcare Partners.

Becton, Dickinson and Company to Report Q3, 2022 Results on Aug 04, 2022

Becton, Dickinson and Company Announces Management Changes

Becton, Dickinson and Company Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Virus

BD Announces Voluntary Recall on Intraosseous Products

Becton, Dickinson and Company Appoints Simon Campion as Executive Vice President and President of the Medical Segment, Effective July 1, 2022

Becton, Dickinson and Company (NYSE:BDX) (BD) entered into a definitive agreement to acquire Parata Systems, LLC from Frazier Healthcare Partners for $1.5 billion.

Becton, Dickinson and Company Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Platform in the U.S

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2022

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 30, 2022

New Becton, Dickinson and Company Reagents Enable Researchers to Break Through Resolution Boundaries in Flow Cytometry

Becton, Dickinson and Company to Report Q2, 2022 Results on May 05, 2022

Becton, Dickinson and Company Announces Management Changes

Becton, Dickinson and Company Announces Retirement of Alberto Mas as Executive Vice President and President of the Medical Segment, Effective September 30, 2022

Becton, Dickinson and Company Appoints William Bill Brown to Board of Directors

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company Revises Revenue Guidance for the Fiscal Year 2022

Becton, Dickinson and Company (NYSE:BDX) acquired Cytognos, SL from Vitro S.A.

Becton, Dickinson and Company Receives 510(K) Clearance from the U.S. Food and Drug Administration for the BD Kiestra™ Identifa System

BD Announces New Distribution and Retail Partners for Bd Veritor At-Home Covid-19 Test

Becton, Dickinson and Company (NYSE:BDX) acquired Scanwell Health, Inc.

BD Expands Fully Automated High-Throughput Molecular Diagnostic Platform for Core Labs

Becton, Dickinson and Company (NYSE:BDX) acquired Tissuemed Ltd.

Becton, Dickinson and Company (NYSE:BDX) acquired Venclose, Inc.

Becton, Dickinson and Company Receives Emergency Use Authorization for First At-Home COVID-19 Test to Use Smartphone to Interpret, Deliver Results

BD (Becton, Dickinson and Company) Announces the Launch of A New Benchtop Cell Analyzer

Becton, Dickinson and Company (NYSE:BDX) acquired ZebraSci Inc.

BD Announces Expanded 510(k) Clearance for At-Home System for Ascites

Becton, Dickinson and Company Launches Urine Culture Application

Becton, Dickinson and Company (NYSE:BDX) acquired BD Surgiphor Sterile Wound Irrigation System from Orthophor, LLC.

Becton, Dickinson and Company Announces Industry-First CE Marked Assay for HPV Screening from At-Home Self-Collected Vaginal Samples

BD Announces Intent to Spin Off Diabetes Care Business to Enhance Focus on Innovation and Priority Growth Markets

BD Announces Enrollment in Post-Market Studies of the WavelinQ™ Arteriovenous Endovascular Fistula

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 30, 2021

BD Announces FDA 510(k) Submission for BD Alaris™ System

BD Announces Collaboration with ImageMover for Rapid Antigen Test Reporting

Becton, Dickinson and Company (NYSE:BDX) acquired GSL Solutions, Inc.

BD and Scanwell Health Announces Collaboration for At-Home Rapid Test for COVID-19

BD Announces Emergency Use Authorization, CE Mark for Combination Molecular Diagnostic to Detect SARS-CoV-2, Influenza A+B in Single Test

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2021

Becton, Dickinson and Company Announces New Clinical Data Found Robust Evidence Using A Vascular Care Solution

Becton, Dickinson and Company Announces Board Changes

Desglose de ingresos y gastos
Beta